Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
about
Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brainIncreased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brainProteomic analysis of rat hippocampus exposed to the antidepressant paroxetineEvaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.Pharmaceuticals as neuroendocrine disruptors: lessons learned from fish on Prozac.Review of sertraline and its clinical applications in psychiatric disorders.Pharmacotherapies in the management of obsessive-compulsive disorder.Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives.Cyclic-AMP mediated regulation of ABCB mRNA expression in mussel haemocytesEarly-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.Review of sertraline in post-traumatic stress disorder.Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feedingTherapeutic drug monitoring of non-tricyclic antidepressant drugs.Estrogenic/antiestrogenic activity of selected selective serotonin reuptake inhibitorsSertraline for the treatment of depression in coronary artery disease and heart failure.Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons.Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain.Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neuronsFluoxetine pharmacogenetics in child and adult populations.Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors.Sigma-1 receptor ligands inhibit catecholamine secretion from adrenal chromaffin cells due to block of nicotinic acetylcholine receptors.Selective serotonin reuptake inhibitors and β-blocker transformation products may not pose a significant risk of toxicity to aquatic organisms in wastewater effluent-dominated receiving waters.Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.Simultaneous determination of 24 antidepressant drugs and their metabolites in wastewater by ultra-high performance liquid chromatography-tandem mass spectrometry.A Novel Liquid-Liquid Extraction for the Determination of Sertraline in Tap Water and Waste Water at Trace Levels by GC-MS.Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims.Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.Optimization of alcohol-assisted dispersive liquid-liquid microextraction by experimental design for the rapid determination of fluoxetine in biological samples.Fluoxetine inhibits aggressive behaviour during parental care in male fighting fish (Betta splendens, Regan).Square‐Wave Adsorptive‐Stripping Voltammetric Detection in the Quality Control of Fluoxetine
P2860
Q24678282-D7F94C5A-1487-41F3-B1B9-B9D75C2D67E7Q28539770-B6516C66-8B9D-4B95-BC19-8E0313366425Q28567997-1987D625-3FCA-4F90-BD68-F95E6D1F93A8Q30475712-A16CA891-C489-4C13-82F9-0EE8F4ED5A47Q34203601-F73197A2-D76F-4B24-B1EF-82DBBF805939Q34241066-AB043AB1-B54A-459D-AB2D-5C2C2E79490BQ34547177-9CF3DEB4-B4B3-4094-8E5C-55A7FF990951Q34643816-BFC6CF50-6D1A-4C18-8A4A-3336D5CA0165Q34675010-4EF92533-EF43-481B-9738-5EEEA472E487Q34714284-D72639ED-D51C-41F9-BFE2-AF2284F147E8Q34974832-DCD85B06-97E2-4FA3-9DAC-FD3A1F60A5A9Q35575008-4EE5EF1C-79A1-41FF-B6DB-5A6D2DCAE49FQ35827404-2C9937F6-5668-4978-B98F-7CE97A36A891Q35970340-1285D682-FE51-4E88-B29F-2AEEE716CF3EQ36247788-DAA42E7F-EB20-4174-8CE5-D5882A4F5F4BQ36895857-2FBEA258-FE52-406F-A585-E30D8E23D572Q36989116-7021B485-382E-46BC-8462-5DBDCBE19DE1Q37137501-6FC8F46C-C5C9-4BC9-BF27-D1C4DF5E0C41Q37236791-D07D9924-F52C-4A4F-B868-450DC4DB25CDQ38025986-B92BD720-73EC-4A1E-A2A9-BA36D784E71CQ38052726-B009E9D8-95FA-4CDD-9BC8-189F76B6531EQ38620929-118AEF04-3224-4530-BF82-90CDD32CD905Q39023960-63F44DE0-6441-4872-A698-E15695B8C97BQ39968946-DCFC59C7-9815-4746-932C-3BE53ED3A310Q43261539-EBF25D67-E0B6-48D0-9042-7A4DEBF592CAQ43311738-F09F3097-44CC-4D39-96D5-2553CAFA470EQ48024841-DEA586B3-BD3E-4AF7-8C11-CC3CB7E47F14Q48118637-BDFBA977-E004-43B1-8876-48D256E0C4A9Q50475979-55CBA601-A639-41E5-9CFE-0B3F3319E07DQ51736030-F6B6E02D-D12D-4AF3-A6D9-C7D27B84638EQ52653596-E17BE1BC-8CDA-45A1-9B69-1DF33295F60CQ56991215-0E29045D-2E4C-4D4B-81CB-4B2172EC714E
P2860
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@ast
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@en
type
label
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@ast
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@en
prefLabel
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@ast
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@en
P356
P1476
Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
@en
P2093
P2888
P304
P356
10.1023/A:1006934807375
P577
1999-08-01T00:00:00Z
P6179
1048025959